Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:18:52 ON 19 JUL 2007

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 08:19:05 ON 19 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 18 Jul 2007 (20070718/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s GAG
         13467 GAG
          1737 GAGS
L1       14136 GAG
                (GAG OR GAGS)

=> s l1 and cancer?
        338275 CANCER?
L2         327 L1 AND CANCER?

=> s l2 and inhibit?
       1943358 INHIBIT?
L3         112 L2 AND INHIBIT?

=> s l3 and ECAM?
            75 ECAM?
L4           1 L3 AND ECAM?

=> d ibib abs hitstr tot

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2004:681500  CAPLUS
DOCUMENT NUMBER:         141:195321
TITLE:                   Pharmaceutical compositions comprising
                         thieno[2,3-c]pyridines
INVENTOR(S):             Gregor, Paul; Harris, Nicholas; Koppel, Juraj; Zhuk,
                         Regina
PATENT ASSIGNEE(S):      Rimonyx Pharmaceuticals Ltd., Israel
```

SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069149	A2	20040819	WO 2004-IL121	20040205
WO 2004069149	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210241	A1	20040819	AU 2004-210241	20040205
CA 2515102	A1	20040819	CA 2004-2515102	20040205
EP 1589970	A2	20051102	EP 2004-708427	20040205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1771037	A	20060510	CN 2004-80009369	20040205
JP 2006516610	T	20060706	JP 2006-502633	20040205
IN 2005DN03405	A	20070601	IN 2005-DN3405	20050801
US 2006135529	A1	20060622	US 2005-543065	20051019
PRIORITY APPLN. INFO.:			IL 2003-154306 A	20030205
			WO 2004-IL121 W	20040205

OTHER SOURCE(S): MARPAT 141:195321

AB The present invention provides thieno[2,3-c]pyridines, and pharmaceutical compns. comprising thieno[2,3-c]pyridines. The compds. capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion mols. (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders. Thus, a capsule contained a thieno[2,3-c]pyridine 40.0, starch 109.0, and Mg stearate 1.0 mg.

```
=> s l3 and heparin?
         53899 HEPARIN?
L5          20 L3 AND HEPARIN?

=> s l5 and py<2003
      22885865 PY<2003
L6            7 L5 AND PY<2003

=> d ibib abs hitstr tot

L6   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2005:1293546  CAPLUS
DOCUMENT NUMBER:         144:40813
TITLE:                   Selectively treating cancer and angiogenesis
                         associated diseases with specific glycosaminoglycan
                         polymers
INVENTOR(S):             Deangelis, Paul L.
PATENT ASSIGNEE(S):      Board of Regents of University of Oklahoma, USA
SOURCE:                  U.S. Pat. Appl. Publ., 92 pp., Cont.-in-part of U.S.
                         Ser. No. 542,248.
                         CODEN: USXXCO
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005272696	A1	20051208	US 2005-172145	20050630
US 6444447	B1	20020903	US 1999-437277	19991110 <--
US 2003104601	A1	20030605	US 2001-842484	20010425
US 2003099967	A1	20030529	US 2002-142143	20020508
US 2006188966	A1	20060824	US 2002-195908	20020715
US 2003113845	A1	20030619	US 2002-217613	20020812
US 6987023	B2	20060117		
US 2004132143	A1	20040708	US 2003-642248	20030815
US 7223571	B2	20070529		
US 2005059118	A1	20050317	US 2004-990844	20041117
US 2005266460	A1	20051201	US 2005-124215	20050509
US 7232684	B2	20070619		
AU 2005287397	A1	20060330	AU 2005-287397	20050630
CA 2572154	A1	20060330	CA 2005-2572154	20050630
WO 2006033693	A2	20060330	WO 2005-US23452	20050630
WO 2006033693	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1768678	A2	20070404	EP 2005-788952	20050630
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 2006141535	A1	20060629	US 2006-352664	20060213

PRIORITY APPLN. INFO.:

US 1998-80414P	P	19980402
US 1998-107929P	P	19981111
US 1999-283402	B2	19990401
US 1999-437277	A2	19991110
US 2000-199538P	P	20000425
US 2001-842484	B2	20010425
US 2001-289554P	P	20010508
US 2002-142143	A2	20020508
US 2002-195908	A2	20020715
US 2002-404356P	P	20020816
US 2003-479432P	P	20030618
US 2003-491362P	P	20030731
US 2003-642248	A2	20030815
US 2004-584442P	P	20040630
US 1998-178851	B2	19981026
US 2000-245320P	P	20001102
US 2001-842930	A3	20010425
US 2001-296386P	P	20010606
US 2001-303691P	P	20010706
US 2001-305263P	P	20010713
US 2001-313258P	P	20010817
US 2001-345497P	P	20011109
US 2002-350642P	P	20020122

US 2002-391787P	P	20020620
US 2002-217613	A1	20020812
US 2004-990844	A3	20041117
US 2005-172145	A	20050630
WO 2005-US23452	W	20050630

AB The present invention demonstrates that defined, specific GAG mols. have discerned differential effects, and that different types of cancers are prevented from proliferating and/or killed by oligosaccharides of different sizes; one size sugar does not treat all cancers effectively. Likewise, certain size GAGs have more potent angiogenic properties; thus, mixts. of different sizes of GAG mols. are not optimal. Therefore, the present invention is directed to methods of "personalized medicine", in which customized defined, specific GAG mols. are administered to a patient, wherein the defined, specific GAG mols. are chosen based on the specific ailment from which the patient is suffering and/or the response of in vitro testing of the ability of the defined, specific GAG mols. to treat, inhibit and/or prevent the ailment in a sample from the patient.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:924013 CAPLUS
DOCUMENT NUMBER: 142:109434
TITLE: Novel acharan sulfate lyases specifically degrading acharan sulfate, preparing method and use thereof
INVENTOR(S): Kim, Byeong Taek; Kim, Dong Hyun; Kim, Wan Seok; Kim, Young Sik
PATENT ASSIGNEE(S): S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2002046294	A	20020621	KR 2000-75605	20001212 <--
PRIORITY APPLN. INFO.:			KR 2000-75605	20001212

AB Novel acharan sulfate lyases specifically degrading acharan sulfate, a preparing method and a use thereof are provided, therefore the acharan sulfate lyase having improved substrate specificity and stability can be produced and it can be useful in producing acharan sulfate oligosaccharides inhibiting the metastasis of cancer. The acharan sulfate lyase capable of degrading glycosaminoglycans (GAG) is isolated from Bacteroides stercoris HJ-15, wherein glycosaminoglycans (GAG) are acharan sulfate, heparin and heparan sulfate; the acharan sulfate lyase has 82,500 Da of mol. weight and optimal pH of 7.0 to 7.2 and optimal temperature of 42 to 45 deg. C; and the activity of enzyme is increased by Mg2+ or Mn2+ and inhibited by Cu2+ or Ni2+. The method for producing the acharan sulfate lyase comprises the steps of: culturing Bacteroides stercoris in an appropriate medium; recovering the cultured cells and preparing cell extract; and subjecting the cell extract to chromatog., wherein the chromatog. is selected from QAE-cellulose, DEAE-cellulose, CM-Sephadex C-50, hydroxyapatite, CM-Sephadex C-25 and Hi-Trap SP.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:937303 CAPLUS
DOCUMENT NUMBER: 138:20443
TITLE: Endocrine disruptor screening using DNA chips of

endocrine disruptor-responsive genes
INVENTOR(S): Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto, Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin
PATENT ASSIGNEE(S): Takara Bio Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 386 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2002355079	A	20021210	JP 2002-69354		20020313 <--
PRIORITY APPLN. INFO.:			JP 2001-73183	A	20010314
			JP 2001-74993	A	20010315
			JP 2001-102519	A	20010330

AB A method and kit for detecting endocrine-disrupting chems. using DNA microarrays are claimed. The method comprises preparing a nucleic acid sample containing mRNAs or cDNAs originating in cells, tissues, or organisms which have been brought into contact with a sample containing the endocrine disruptor. The nucleic acid sample is hybridized with DNA microarrays having genes affected by the endocrine disruptor or DNA fragments originating in these genes have been fixed. The results obtained are then compared with the results obtained with the control sample to select the gene affected by the endocrine disruptor. Genes whose expression is altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate, dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl phthalate, diethylstilbestrol (DES), and 17-β estradiol (E2), were found in mice by DNA chip anal.

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:519074 CAPLUS
DOCUMENT NUMBER: 138:83028
TITLE: Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis
AUTHOR(S): Pumphrey, Carla Y.; Theus, Allison M.; Li, Shulin; Parrish, Rudolph S.; Sanderson, Ralph D.
CORPORATE SOURCE: Arkansas Cancer Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA
SOURCE: Cancer Research (2002), 62(13), 3722-3728
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The soluble form of the syndecan-1 heparan sulfate proteoglycan acts as a tumor suppressor mol. that inhibits growth and induces apoptosis of some cancer cell lines in vitro. Analogs of syndecan-1 were produced by carbodiimide (EDAC) conjugation of glycosaminoglycan (GAG) chains to a protein scaffold, thereby generating synthetic proteoglycans that were evaluated for anticancer properties. Surprisingly, when analyzing activities of the controls, the authors discovered that EDAC modified GAG chains inhibit myeloma cell viability even in the absence of protein. Here, the authors describe the production and the activities of these novel mols. called neoglycans. The GAG chains heparin and chondroitin sulfate (CS) were exposed to EDAC to generate the neoglycans neoheparin and neoCS, resp. Heparin and CS in the absence of EDAC modification have no effect or a slight growth promoting effect on cancer and normal cell lines. However, neoheparin and neoCS

substantially reduce cell viability by induction of apoptosis of myeloma and breast cancer cells in vitro. NeoCS when injected directly into breast tumors growing in nude mice reduces or abolishes their growth without causing apparent toxicity to the adjacent normal tissue. The neoglycans need not be continuously present in cell cultures because a short pulse exposure is sufficient to reduce cell viability. NeoCS fractions purified by size exclusion chromatog. reduce myeloma cell viability, confirming the specificity of neoglycan activity. Collectively, the results of this study demonstrate the anticancer activities of this new class of GAG chain-based mols. and provide the foundation for future development of neoglycans as novel therapeutic agents.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:471952 CAPLUS

DOCUMENT NUMBER: 137:167275

TITLE: The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is a heparan sulfate/chondroitin sulfate-containing proteoglycan

AUTHOR(S): Engbring, Jean A.; Hoffman, Matthew P.; Karmand, Arezo J.; Kleinman, Hynda K.

CORPORATE SOURCE: Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, 20892-4370, USA

SOURCE: Cancer Research (2002), 62(12), 3549-3554
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Exposure to AG73, a synthetic peptide (LQVQLSIR) from the C-terminal region of the laminin α1 chain, induces a malignant phenotype in B16F10 melanoma cells. Coinjection of this peptide with the cells results in an increase of lung tumors and also the formation of liver tumors in .apprx.50% of the mice (W. H. Kim et al., Int. J. Cancer, 77: 632-639, 1998). Here we have characterized the cell surface receptor and its functional groups on B16F10 cells. Peptide affinity chromatog. identified a cell surface protein eluting with 1 M NaCl, which ran in SDS gels as a broad band of Mr .apprx.150,000-200,000. Digestion with heparitinase and chondroitinase produced a core protein of lower mol. weight (Mr .apprx.90,000). Involvement of the glycosaminoglycan (GAG) side chains was demonstrated by inhibition of cell binding to the peptide by heparin, heparan sulfate, and chondroitin sulfate B, but not by chondroitin sulfates A or C, or hyaluronic acid. The IC50 for heparin was the lowest, followed by heparan sulfate, then chondroitin sulfate B, suggesting that the overall sulfation of the GAG side chain is critical. This was confirmed by inhibition of attachment with chemical modified heparin and heparan sulfate, which also showed that N or O linkages were not important for function. Using sized heparin fragments to inhibit cell binding to the peptide demonstrated that 16-mer is the min. length required. B16F10 cells form a network when grown on Matrigel, and this is prevented by addition of the AG73 peptide. The GAGs alone did not affect network formation, but heparin, heparan sulfate, and chondroitin sulfate B reversed the inhibitory effect of the peptide, whereas other GAGs were inactive. Furthermore, removal of cell surface GAGs inhibited cell attachment to the peptide. Cells treated with glycosidases and coinjected with the peptide formed liver tumors equal to the control group receiving no peptide, suggesting that the GAGs play an early role in peptide-mediated tumor metastasis. These data indicate that the B16F10 cell receptor for a laminin metastasis-promoting sequence is a heparan sulfate/chondroitin

sulfate-containing proteoglycan, and these GAG side chains are functionally important in the cell-peptide interaction.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:90603 CAPLUS
DOCUMENT NUMBER: 136:129048
TITLE: Neoglycan anticancer agents and uses thereof
INVENTOR(S): Sanderson, Ralph D.; Pumphrey, Carla Y.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 479,139.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002013264	A1	20020131	US 2001-921032		20010802 <--
PRIORITY APPLN. INFO.:			US 1999-115053P	P	19990108
			US 2000-479139	A2	20000107

AB The invention describes the production of neoglycans, compds. capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor mol. that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogs of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), resp. named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further anal. revealed the neoglycan compds. severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:286528 CAPLUS
DOCUMENT NUMBER: 127:16108
TITLE: Role of proteoglycans in cell adhesion of prostate cancer cells. From review to experiment
AUTHOR(S): Schamhart, D. H. J.; Kurth, K. H.
CORPORATE SOURCE: Dep. Urology, Univ. Amsterdam, Amsterdam, 1105 AZ, Neth.
SOURCE: Urological Research (1997), 25(Suppl.2), S89-S96
CODEN: URLRA5; ISSN: 0300-5623
PUBLISHER: Springer
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB The effects of (free) glycosaminoglycans (GAGs), major functional substructures of proteoglycans (PGs), were studied on cell adhesion and proliferation. Natural GAGs (heparin, heparan, dermatan, chondroitin-4 and chondroitin-6 sulfate) added to cells during cell adhesion had no effect on cell proliferation. Semisynthetic, GAG-like pentosan polysulfate (PPS) inhibited proliferation of the prostatic cell lines LNCaP and DU145, but not of the less anchorage-dependent PC-3 cells. In contrast to the natural GAGs, PPS inhibited cell adhesion. This suggests the involvement of PGs of the cell surface in cell adhesion, affecting various

processes (proliferation, angiogenesis, metastasis) of prostate tumor progression. These data are preceded by a review with many refs. on the regulation of cell growth and motility by proteoglycans.

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        37.05      37.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -6.24      -6.24

FILE 'STNGUIDE' ENTERED AT 08:21:52 ON 19 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d his

     (FILE 'HOME' ENTERED AT 08:18:52 ON 19 JUL 2007)

     FILE 'CAPLUS' ENTERED AT 08:19:05 ON 19 JUL 2007
L1         14136 S GAG
L2           327 S L1 AND CANCER?
L3           112 S L2 AND INHIBIT?
L4             1 S L3 AND ECAM?
L5            20 S L3 AND HEPARIN?
L6             7 S L5 AND PY<2003

     FILE 'STNGUIDE' ENTERED AT 08:21:52 ON 19 JUL 2007

=> log y
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.18      37.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -6.24

STN INTERNATIONAL LOGOFF AT 08:23:43 ON 19 JUL 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:30:04 ON 19 JUL 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 07:31:36 ON 19 JUL 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JUL 2007 HIGHEST RN 942651-59-4
DICTIONARY FILE UPDATES: 18 JUL 2007 HIGHEST RN 942651-59-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10543065.str



chain nodes :
10 11 12 19 21 22 23 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
ring/chain nodes :
20
chain bonds :
8-10 10-11 10-23 11-12 11-13 14-26 15-25 16-19 17-28 18-27 19-20 19-21 19-22

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-10 10-11 11-12 16-19 19-20 19-21 19-22
exact bonds :
5-7 6-9 7-8 8-9 10-23 11-13 14-26 15-25 17-28 18-27
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:31:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3206 TO 4914
PROJECTED ANSWERS: 2973 TO 4627

L2 50 SEA SSS SAM L1

=> d 1-5

L2 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 922694-45-9 REGISTRY
ED Entered STN: 22 Feb 2007
CN INDEX NAME NOT YET ASSIGNED
MF C22 H28 N4 O6 S2
SR Chemical Library
Supplier: Aurora Fine Chemicals



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 2 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 922570-34-1 REGISTRY
ED Entered STN: 22 Feb 2007
CN INDEX NAME NOT YET ASSIGNED
MF C24 H28 N4 O5 S2
SR Chemical Library
Supplier: Aurora Fine Chemicals



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 3 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 922569-04-8 REGISTRY
ED Entered STN: 22 Feb 2007
CN INDEX NAME NOT YET ASSIGNED
MF C25 H26 N4 O6 S2
SR Chemical Library
Supplier: Aurora Fine Chemicals



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 4 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 922476-65-1 REGISTRY
ED Entered STN: 22 Feb 2007
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(cyclopropylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-methyl-, ethyl ester (CA INDEX NAME)
MF C22 H27 N3 O5 S2
SR Chemical Library
Supplier: Aurora Fine Chemicals



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 5 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 922475-73-8 REGISTRY
ED Entered STN: 22 Feb 2007
CN INDEX NAME NOT YET ASSIGNED
MF C23 H31 N3 O5 S2
SR Chemical Library
Supplier: Aurora Fine Chemicals



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> s l1 full
FULL SEARCH INITIATED 07:33:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3781 TO ITERATE

100.0% PROCESSED 3781 ITERATIONS 3515 ANSWERS
SEARCH TIME: 00.00.01

L3 3515 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 182.75 183.38

FILE 'CAPLUS' ENTERED AT 07:33:39 ON 19 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 18 Jul 2007 (20070718/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1331198 CAPLUS
DOCUMENT NUMBER: 146:184625
TITLE: 3D pharmacophore based virtual screening of T-type calcium channel blockers
AUTHOR(S): Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo; Rhim, Hyewhon; Koh, Hun Yeong; Lee, Jung-Ha; Jeong, Seong-Woo; Pae, Ae Nim
CORPORATE SOURCE: Life Science Division, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(2), 1091-1105
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Virtual screening of the com. databases was done by using a three dimensional pharmacophore previously developed for T-type calcium channel blockers using CATALYST program. Biol. evaluation of 25 selected virtual hits resulted in the discovery of a highly potent compound (I) with IC50 value of 0.10 μM, eight times as potent as the known selective T-type calcium channel blocker, mibefradil. Search for similar compds. yielded several hits with micro-molar IC50 values and high T-type calcium channel selectivity. Based on the structure of the virtual hits, small mol. libraries with novel scaffolds were designed, synthesis and biol. evaluation of which are currently in progress. This result shows a successful example of ligand based drug discovery of potent T-type calcium channel blockers.

IT 449767-52-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3D pharmacophore based virtual screening of T-type calcium channel blockers)

RN 449767-52-6 CAPLUS

CN Thieno[2,3-c]pyridine-3-carboxylic acid, 6-ethyl-4,5,6,7-tetrahydro-2-[[4-[(methylphenylamino)sulfonyl]benzoyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:681500 CAPLUS
DOCUMENT NUMBER: 141:195321
TITLE: Pharmaceutical compositions comprising thieno[2,3-c]pyridines
INVENTOR(S): Gregor, Paul; Harris, Nicholas; Koppel, Juraj; Zhuk, Regina
PATENT ASSIGNEE(S): Rimonyx Pharmaceuticals Ltd., Israel
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069149	A2	20040819	WO 2004-IL121	20040205
WO 2004069149	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210241	A1	20040819	AU 2004-210241	20040205
CA 2515102	A1	20040819	CA 2004-2515102	20040205
EP 1589970	A2	20051102	EP 2004-708427	20040205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1771037	A	20060510	CN 2004-80009369	20040205
JP 2006516610	T	20060706	JP 2006-502633	20040205
IN 2005DN03405	A	20070601	IN 2005-DN3405	20050801
US 2006135529	A1	20060622	US 2005-543065	20051019
PRIORITY APPLN. INFO.:			IL 2003-154306 A	20030205
			WO 2004-IL121 W	20040205

OTHER SOURCE(S): MARPAT 141:195321

AB The present invention provides thieno[2,3-c]pyridines, and pharmaceutical compns. comprising thieno[2,3-c]pyridines. The compds. capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion mols. (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders. Thus, a capsule contained a thieno[2,3-c]pyridine 40.0, starch 109.0, and Mg stearate 1.0 mg.

IT 533904-03-9P 738620-45-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. comprising thieno[2,3-c]pyridines)

RN 533904-03-9 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-N-methyl-2-[[4-[(methylphenylamino)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 738620-45-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



IT 440334-81-6 449767-27-5 449767-88-8
449767-89-9 449768-16-5 449768-37-0
449768-51-8 449768-53-0 449768-67-6
449768-77-8 449768-83-6 449783-27-1
486453-13-8 486453-14-9 486453-16-1
486453-17-2 486453-18-3 486453-20-7
486453-21-8 486453-22-9 486453-24-1
486453-25-2 486453-26-3 486453-27-4
486453-29-6 489470-30-6 489470-38-4
489470-54-4 489470-89-5 489470-97-5
489470-98-6 489471-00-3 489471-01-4
489471-04-7 489471-11-6 489471-16-1
489471-25-2 489471-29-6 489471-31-0
489471-38-7 489471-39-8 524694-99-3
524695-12-3 524706-73-8 533895-61-3
533904-54-0 681264-20-0 681439-14-5
681439-15-6 738620-43-4 738620-44-5
738620-48-9 738620-49-0 738620-50-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising thieno[2,3-c]pyridines)

RN 440334-81-6 CAPLUS

CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 449767-27-5 CAPLUS

CN Thieno[2,3-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-2-[[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]benzoyl]amino]-(9CI) (CA INDEX NAME)



RN 449767-88-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 449767-89-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 449768-16-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(butylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 449768-37-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 449768-51-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(butylethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449768-53-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-6-(1-methylethyl)-2-[[4-[(methylphenylamino)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 449768-67-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449768-77-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449768-83-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 449783-27-1 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 486453-13-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-14-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(dipropylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-16-1 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(dibutylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-17-2 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(butylmethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-18-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-20-7 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-21-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 486453-22-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 486453-24-1 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(3-methyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-25-2 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(4-methyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-26-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 486453-27-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 486453-29-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[[bis(2-methoxyethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 489470-30-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(dipropylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489470-38-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489470-54-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(hexahydro-1H-azepin-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489470-89-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 489470-97-5 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489470-98-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489471-00-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 489471-01-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(2-methyl-1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 489471-04-7 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 489471-11-6 CAPLUS
CN Thieno[2,3-c]pyridine-6(5H)-carboxylic acid, 3-(2-benzothiazolyl)-2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,7-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 489471-16-1 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(di-2-propenylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 489471-25-2 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 489471-29-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(butylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 489471-31-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(cyclohexylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 489471-38-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[3-(aminocarbonyl)-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridin-2-yl]amino]carbonyl]phenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 489471-39-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 524694-99-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(phenylmethyl)thieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 524695-12-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(methylphenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 524706-73-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 533895-61-3 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)



RN 533904-54-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)



RN 681264-20-0 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridin-2-yl]-4-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 681439-14-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 681439-15-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[[bis(2-methoxyethyl)amino]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (9CI) (CA INDEX NAME)



RN 738620-43-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]amino]carbonyl]phenyl]sulfonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 738620-44-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-2-[[4-[[ethyl(phenylmethyl)amino]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 738620-48-9 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-N-methyl-2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 738620-49-0 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 738620-50-3 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydro-N-4-morpholinyl- (9CI) (CA INDEX NAME)





L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:826913 CAPLUS
DOCUMENT NUMBER: 138:49321
TITLE: Property-based design of GPCR-targeted library
AUTHOR(S): Balakin, Konstantin V.; Tkachenko, Sergey E.; Lang, Stanley A.; Okun, Ilya; Ivashchenko, Andrey A.; Savchuk, Nikolay P.
CORPORATE SOURCE: Chemical Diversity Labs Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Chemical Information and Computer Sciences (2002), 42(6), 1332-1342
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The design of a GPCR-targeted library, based on a scoring scheme for the classification of mols. into "GPCR-ligand-like" and "non-GPCR-ligand-like", is outlined. The methodol. is a valuable tool that can aid in the selection and prioritization of potential GPCR ligands for bioscreening from large collections of compds. It is based on the distillation of knowledge from large databases of GPCR and non-GPCR active agents. The method

employed a set of descriptors for encoding the mol. structures and by training of a neural network for classifying the mols. The mol. requirements were profiled and validated by using available databases of GPCR- and non-GPCR-active agents. The method enables efficient qualification or disqualification of a mol. as a potential GPCR ligand and represents a useful tool for constraining the size of GPCR-targeted libraries that will help speed up the development of new GPCR-active drugs.

IT 478932-86-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(property-based design of GPCR-targeted library)

RN 478932-86-4 CAPLUS

CN Thieno[2,3-c]pyridine-3-carboxylic acid, 6-ethyl-4,5,6,7-tetrahydro-2-[[4-[(4,6,6-trimethyl-2-azabicyclo[2.2.1]hept-2-yl)sulfonyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.69	201.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'STNGUIDE' ENTERED AT 07:35:49 ON 19 JUL 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d his

(FILE 'HOME' ENTERED AT 07:30:04 ON 19 JUL 2007)

FILE 'REGISTRY' ENTERED AT 07:31:36 ON 19 JUL 2007
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 3515 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:33:39 ON 19 JUL 2007
L4 3 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 07:35:49 ON 19 JUL 2007

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	201.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

STN INTERNATIONAL LOGOFF AT 07:38:19 ON 19 JUL 2007